MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study

BMC Medical Genetics

Volumn 16, Issue 1, 2015, Pages

  Hsiao, Pi Jung ^a,b,c   Lee, Mei Yueh ^a,b   Wang, Yeng Tseng ^d   Jiang, He Jiun ^a,b   Lin, Pi Chen ^a,b   Yang, Yi Hsin Connie ^e   Kuo, Kung Kai ^b,c  

^a Division of Endocrinology and Metabolism   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apob containing lipoproteins; LDL C; Microsomal triglyceride transfer protein (MTP); Non alcoholic fatty liver disease (NAFLD); Non HDL C; Q297H polymorphism

Indexed keywords

APOLIPOPROTEIN B; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; CARRIER PROTEIN; CHOLESTEROL;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FATTY ACID BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HOMEOSTASIS; HOMOZYGOTE; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID HOMEOSTASIS; MAJOR CLINICAL STUDY; MALE; MTTP GENE; NONALCOHOLIC FATTY LIVER; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROTEIN SECONDARY STRUCTURE;

ADULT; CARRIER PROTEINS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY;

EID: 84944061167     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-015-0242-6     Document Type: Article

References (39)

1. Miller SA, Burnett JR, Leonis MA, McKnight CJ, van Bockxmeer FM, Hooper AJ. Novel missense MTTP gene mutations causing abetalipoproteinemia. Biochim Biophys Acta. 2014;1842(10):1548-54.
2. Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr Metabol. 2012;9:14.
3. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3:19.
4. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014;25(3):161-8.
5. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885-904.
6. Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol. 2013;19(3):210-5.
7. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434-41.
8. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44(1):22-32.
9. Di Filippo M, Moulin P, Roy P, Samson-Bouma ME, Collardeau-Frachon S, Chebel-Dumont S, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol. 2014;61(4):891-902.
10. Khatun I, Walsh MT, Hussain MM. Loss of both phospholipid and triglyceride transfer activities of microsomal triglyceride transfer protein in abetalipoproteinemia. J Lipid Res. 2013;54(6):1541-9.
11. Zak A, Jachymova M, Tvrzicka E, Vecka M, Duffkova L, Zeman M, et al. The influence of polymorphism of -493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. J Nutr Biochem. 2008;19(9):634-41.
12. Peng XE, Wu YL, Lu QQ, Hu ZJ, Lin X. MTTP polymorphisms and susceptibility to non-alcoholic fatty liver disease in a Han Chinese population. Liver Int. 2014;34(1):118-28.
13. Musso G, Gambino R, Cassader M. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J Nutr Biochem. 2010;21(9):834-40.
14. Chen SP, Tan KC, Lam KS. Effect of the microsomal triglyceride transfer protein -493 G/T polymorphism and type 2 diabetes mellitus on LDL subfractions. Atherosclerosis. 2003;167(2):287-92.
15. Aminoff A, Ledmyr H, Thulin P, Lundell K, Nunez L, Strandhagen E, et al. Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease. J Lipid Res. 2010;51(1):103-11.
16. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36(5):1073-81.
17. Roy A, Xu D, Poisson J, Zhang Y. A protocol for computer-based protein structure and function prediction. J Vis Exp. 2011;57, e3259.
18. Worth CL, Preissner R, Blundell TL. SDM-a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 2011;39(Web Server issue):W215-22.
19. Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol. 1998;18(5):756-61.
20. Lundahl B, Skoglund-Andersson C, Caslake M, Bedford D, Stewart P, Hamsten A, et al. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles. Am J Physiol Endocrinol Metab. 2006;290(4):E739-45.
21. St-Pierre J, Lemieux I, Miller-Felix I, Prud'homme D, Bergeron J, Gaudet D, et al. Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men. Atherosclerosis. 2002;160(2):317-24.
22. Bohme M, Grallert H, Fischer A, Gieger C, Nitz I, Heid I, et al. MTTP variants and body mass index, waist circumference and serum cholesterol level: Association analyses in 7582 participants of the KORA study cohort. Mol Genet Metab. 2008;95(4):229-32.
23. Talmud PJ, Palmen J, Miller G, Humphries SE. Effect of microsomal triglyceride transfer protein gene variants (-493G>T, Q95H and H297Q) on plasma lipid levels in healthy middle-aged UK men. Ann Hum Genet. 2000;64(Pt 4):269-76.
24. Ledmyr H, Karpe F, Lundahl B, McKinnon M, Skoglund-Andersson C, Ehrenborg E. Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. J Lipid Res. 2002;43(1):51-8.
25. Zheng W, Wang L, Su X, Hu XF. MTP -493G>T polymorphism and susceptibility to nonalcoholic fatty liver disease: a meta-analysis. DNA Cell Biol. 2014;33(6):361-9.
26. Gordon DA, Jamil H, Gregg RE, Olofsson SO, Boren J. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem. 1996;271(51):33047-53.
27. Lehner R, Lian J, Quiroga AD. Lumenal lipid metabolism: implications for lipoprotein assembly. Arterioscler Thromb Vasc Biol. 2012;32(5):1087-93.
28. Ledmyr H, Ottosson L, Sunnerhagen M, Ehrenborg E. The Ile128Thr polymorphism influences stability and ligand binding properties of the microsomal triglyceride transfer protein. J Lipid Res. 2006;47(7):1378-85.
29. Segrest JP, Jones MK, Dashti N. N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a "lipid pocket" model for self-assembly of apob-containing lipoprotein particles. J Lipid Res. 1999;40(8):1401-16.
30. Dashti N, Gandhi M, Liu X, Lin X, Segrest JP. The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry. 2002;41(22):6978-87.
31. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, Nielsen LB, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999;103(9):1287-98.
32. Khatun I, Zeissig S, Iqbal J, Wang M, Curiel D, Shelness GS, et al. Phospholipid transfer activity of microsomal triglyceride transfer protein produces apolipoprotein B and reduces hepatosteatosis while maintaining low plasma lipids in mice. Hepatology. 2012;55(5):1356-68.
33. Dikkers A, Annema W, de Boer JF, Iqbal J, Hussain MM, Tietge UJ. Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice. J Lipid Res. 2014;55(5):816-25.
34. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082-98.
35. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022-32.
36. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62(23):2178-84.
37. Davis KA, Miyares MA. Lomitapide: a novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm. 2014;71(12):1001-8.
38. Lin M, Zhao S, Shen L, Xu D. Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition. Drug Saf. 2014;37(4):213-24.
39. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22(12):2118-23.